LXRX News and Press, Lexicon Pharmaceuticals Inc. From 11/14/22

Achieved primary endpoint for reduction in average daily pain score (ADPS) at week 6 Significant benefits demonstrated on burning pain and on pain interference with sleep No evidence of withdrawal symptoms or rebound pain after treatment ended Conference Call...

THE WOODLANDS, Texas, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the 13 th Annual Jefferies London Healthcare Conference, taking place November 15-17, 2022. Jeff Wade, Lexicon’s president and ...

Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2022 Earnings Conference Call November 09, 2022 5:00 PM ET Company Participants Mike Kelly – Investor Relations Lonnel Coats – Chief Executive Officer Jeff Wade – President and Chief Financial Officer ...

Lexicon Pharmaceuticals press release ( NASDAQ: LXRX ): Q3 GAAP EPS of -$0.13. As of September 30, 2022, Lexicon had $136.2 million in cash and investments, as compared to $86.7 million as of December 31, 2021 For further details see: Lexicon Pharmaceuticals GAAP...

NDA for Sotagliflozin Remains on Track for May 2023 PDUFA Date Following Mid-Cycle Review Meeting Final Data from Successful RELIEF-DPN-1 Study of LX9211 in Painful Diabetic Neuropathy to Be Presented at 16 th Annual Pain Therapeutics Summit Next Week ...

THE WOODLANDS, Texas, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the final results from the Phase 2 RELIEF-DPN-1 trial of its investigational drug LX9211, a novel, highly selective inhibitor of adaptor-associated kinase 1 (AAK...

THE WOODLANDS, Texas, Nov. 06, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that a new analysis of results from the SOLOIST-WHF Phase 3 outcomes study of its investigational heart failure treatment sotagliflozin, was presented at the America...

Post hoc analysis of clinical data from the SCORED trial presented at the American Society of Nephrology Kidney Week 2022 annual scientific meeting, including evidence that : Sotagliflozin significantly reduced urine albumin-to-creatinine ratio (UACR) Sotagliflozin...

THE WOODLANDS, Texas, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its third quarter 2022 financial results on Wednesday, November 9, 2022, after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m...

THE WOODLANDS, Texas, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced the upcoming presentation of new analyses of results from the SOLOIST-WHF and SCORED Phase 3 outcomes studies of its investigational sotagliflozin product at the Ame...